急性リンパ性/リンパ芽球性白血病（ALL）診断市場の世界的動向と2030年までの予測

急性リンパ性/リンパ芽球性白血病（ALL）診断市場の分析と洞察

血液がんは、ここ数十年、世界中で最も一般的ながんです。がんの発生率は、男性、女性ともに上昇傾向にあります。男性の方が女性よりわずかに多く発生します。急性リンパ性白血病 (ALL) は、米国のリンパ系腫瘍の約 2% を占めています。患者は通常、骨髄が腫瘍に置き換わることによって、貧血、血小板減少症、好中球減少症に関連する症状を呈します。白血病の診断治療における激しい競争と、世界中で診断の改善が求められていることから、この分野ではさまざまなサービスの需要が高まっています。さまざまな企業が、急性リンパ性/リンパ芽球性白血病 (ALL) 診断市場に対する世界的な需要の高まりに対応するために、多数の診断製品を発売しています。

しかし、白血病の治療には、治療法、医薬品などを含めて高額な費用がかかることが、最も重要な要因の 1 つです。その結果、長期的には市場の成長が阻害される可能性があります。診断製品のコストは、白血病診断装置ベンダーにとって課題となる可能性のある要素の 1 つです。 

Data Bridge Market Research の分析によると、急性リンパ性/リンパ芽球性白血病 (ALL) 診断の世界市場は、予測期間中に 7.4% の CAGR で成長し、2030 年までに 20 億 8,932 万米ドルに達すると予想されています。白血病診断の需要が急増しているため、製品タイプが市場で最大のセグメントを占めています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。

Market Definition

Acute lymphocytic leukemia (ALL) is a malignancy of B or T-lymphoblasts characterized by uncontrolled proliferation of abnormal, immature lymphocytes and their progenitors, which ultimately leads to the replacement of bone marrow elements and other lymphoid organs resulting in a characteristic disease pattern. B-cells are a specific type of lymph cell that affect a body's immune system. Two types of B-cell leukemia are prolymphocytic leukemia (PLL) and Hairy Cell Leukemia (HCL). Symptoms include fatigue, easy or spontaneous bruising and bleeding, and infections. Additionally, B-symptoms, such as fever, night sweats, and unintentional weight loss, are often present but may be mild, and hepatomegaly, splenomegaly, and lymphadenopathy can be seen in up to half of adults on presentation. Central Nervous System (CNS) involvement is common and can be accompanied by cranial neuropathies or symptoms, predominantly meningeal, related to increased intracranial pressure. T-cell lymphoblastic leukemia is most common among children aged over five years. The increasing cases of cancer worldwide and the rising prevalence of lymphoblastic leukemia are expected to drive segmental T-cell acute lymphoblastic leukemia market growth. These white blood cell acutely influences white platelets called T- lymphocytes. The global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is expected to show significant growth due to the rising prevalence of T-cell acute lymphoblastic leukemia, research and development activities, and high healthcare expenditure.

Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• Growing prevalence of leukemia cancer

All ages can be affected by leukemia. Leukemia can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. Acute lymphoblastic leukemia has the highest emergency presenting rates of any cancer kind, with a leukemia emergency diagnostic rate of 37% on average.

The most frequent form of juvenile cancer is acute lymphoblastic leukemia, a heterogeneous illness defined by unchecked lymphoid progenitor proliferation that typically begins in utero. Although the prevalence of ALL has been rising significantly in recent decades, there is still no apparent cause for this development. Rising maternal obesity rates may be partially responsible for the rise in ALL prevalence.

Thus, acute leukemia incidence has been rising globally due to various risk factors, becoming a significant socio-economic issue. This is expected to act as a driver in the global acute lymphocytic\lymphoblastic leukemia (ALL) diagnostics market.

•  Novel technological advancements in leukemia diagnostics

The most common form of blood cancer, acute lymphoblastic leukemia (ALL), is also one of the main causes of death. The blood is invaded by this form of cancer, which then spreads to nearby organs and bodily systems. Specialists must manually diagnose cancer and non-cancer cells by examining cell images under a microscope and providing labels through annotation. However, this hand microscopic examination is time-consuming and could give an incorrect diagnosis.

The risk of prescribing the incorrect drugs was then reduced using computerized software. The creation of an automatic and reliable classification system became vital to stop the leukemia disease's devastating effects. Multiple segmentation techniques constituted the foundation of the existing leukemia classification algorithms.

The manual examination of stained blood smear microscopy pictures used in current practice for the initial diagnosis of ALL is time-consuming and prone to error. A potent tool for aiding doctors in making medical decisions has emerged: deep learning-based human-centric biomedical diagnostics. Various computer-aided diagnostic techniques have been created to recognize ALL blood pictures automatically.

The development of several new diagnostic methods will increase the market's growth as many new and advanced products are launched. Hence, it is expected to create demand for acute leukemic cancer diagnosis in the global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.

Restraint

• Late diagnosis and poor prognosis of leukemia

Cancer is the leading cause of death globally. By 2030, it is anticipated that there will be 13.1 million more cancer-related deaths per year. However, if they are identified early on and given the right care, some cancers can be cured. The diagnostic process may experience delays in cancer diagnosis. When patients overlook or fail to respond to potentially cancerous signs, patient delays may result. The main cause of delayed presentation is thought to be a lack of public knowledge of early cancer signs, especially if such symptoms are unusual.

The late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to restrain the growth of the global acute lymphocytic\lymphoblastic leukemia (ALL) diagnostics market.

Opportunities

• Increase in diagnostic products for leukemia

A blood-forming tissue cancer impairs the body's capability to combat infection. Bone marrow is one of the blood-forming tissues that can develop leukemia. Numerous varieties include chronic lymphocytic leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. Many patients with leukemia that grow slowly do not exhibit any symptoms. Fatigue, weight loss, recurrent infections, and easy bruising or bleeding are all possible symptoms of leukemia that grow quickly. Treatment results vary greatly. Treatment for leukemia with a slow growth rate may involve monitoring. Chemotherapy for malignant leukemia is occasionally combined with radiation therapy and stem cell transplant.

Thus, the rise in diagnostic product approvals has led to an increased number of highly efficient products in the market for leukemia diagnosis treatment. This is expected to create an opportunity for the global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.

• Government initiatives toward cancer diagnostics

The government plays a major role while taking the initiative for cancer diseases because cancer is a leading disease worldwide. Leukemia has increased very rapidly in individuals in past decades. Leukemia is the most prevalent cancer, with 60,650 new cases in 2022, according to cancer.gov.

There are several initiatives taken by the government that helps boost the market's demand, and these initiatives will increase awareness among people regarding their health and take early diagnosis for better cure and precaution. For this reason, government initiatives towards cancer diagnostics are acting as an opportunity for growing the demand of the global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.

Challenge

• Increased cost, safety, and convenience issue

Leukemia is fatal cancer, and the diagnosis process of leukemia also has safety issues; it is not cost-effective. One of the most costly medical disorders to treat globally is cancer. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their copayment, deductible, and coinsurance costs are rising.

Rising helium shortage and rising risk of excessive radiation exposure are projected to restrict the use of CT scanners, threatening the possibilities of rising capital investments and low benefit-cost ratio for biomarkers. Many hospitals in developing countries cannot invest in diagnostic imaging equipment, which has led to an increase in the use of reconstructed diagnostic imaging due to high expenditures and financial restrictions. Due to the increasing demand for diagnostic imaging operations in these nations, hospitals that can't afford to buy new, cutting-edge imaging systems instead choose to employ refurbished imaging equipment, which could have long-term negative effects.

Henceforth, the current leukemia diagnosis process has safety, cost, and convenience issues, which are expected to challenge the growth of the global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.

Post-COVID-19 Impact on Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market

The cancer diagnostics market has been badly affected by COVID-19. Hospital admissions were limited to non-essential treatment, and clinics were temporarily closed during the pandemic. The implementation of social distancing, blocking the population, and limited access to clinics have greatly affected the market. The slowdown in patient flows and referrals also affected the market growth. However, the market will continue to grow in the post-pandemic period due to the relaxation of previously imposed restrictions.

Manufacturers make various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results in the cancer diagnostics market.

Recent Developments

• In October 2022, Thermo Fisher Scientific Inc. announced that it had entered into a definitive agreement to acquire The Binding Site Group, a global leader in specialty diagnostics. The acquisition will help in the development of the specialty diagnostics segment.
• In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System. This next-generation digital PCR system helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases.

Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Scope

The global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into product type, test type, cancer type, age group, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Product Type

• Instruments
• Consumables & Accessories

On the basis of product type, the global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into instruments, consumables & accessories.

Test Type

• Imaging Test
• Biopsy
• Blood Test
• Others

On the basis of test type, the global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into imaging test, biopsy, blood test, and others.

Cancer Type

•  B-cell Lymphoblastic Leukemia /Lymphoma
• T-cell Lymphoblastic Leukemia

On the basis of cancer type, the global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into B-cell lymphoblastic leukemia/lymphoma and T-cell lymphoblastic leukemia.

By Age Group

• Below 21
• 21-29
• 30-65
• 65 and Above

On the basis of age group, the global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into below 21, 21-29, 30-65, 65 and above.

By Gender

• Male
• Female

On the basis of gender, the global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into male and female.

By End User

• Hospital
• Associated Labs
• Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Others

On the basis of end user, the global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into hospital, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

By Distribution Channel

• Direct Tender
• Retail Sales

On the basis of distribution channel, the global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is segmented into direct tender and retail sales.

Global Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Regional Analysis/Insights

The global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is analyzed, and market size information is provided by country, product type, test type, cancer type, age group, gender, end user, and distribution channel.

Some countries covered in this global acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market are the U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa. Brazil, Argentina, and Rest of South America.

北米は、高い GDP を誇る最大の消費者市場に主要な市場プレーヤーが存在することから、優位に立つと予想されています。米国は、市場における白血病診断の新たな技術的進歩により、成長が見込まれています。ドイツは、新興市場からの需要の増加とヘルスケア産業の拡大により、ヨーロッパ地域で優位に立つと予想されています。中国は、白血病がん診断手術の増加により、アジア太平洋地域で優位に立つと予想されています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個々の市場影響要因と国内規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、販売チャネルの影響も考慮されます。

競争環境と世界の急性リンパ性/リンパ芽球性白血病（ALL）診断市場シェア分析

急性リンパ性/リンパ芽球性白血病 (ALL) 診断の世界市場の競争状況は、競合他社の詳細を提供します。会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、および技術ライフライン曲線などの詳細が含まれます。上記のデータ ポイントは、急性リンパ性/リンパ芽球性白血病 (ALL) 診断の世界市場への会社の重点にのみ関連しています。

急性リンパ性/リンパ芽球性白血病（ALL）診断の世界市場で活動している主要企業には、F. Hoffmann-La Roche Ltd.、Thermo Fisher Scientific, Inc.、QIAGEN、Abbott、Siemens Healthcare GmbH、Merck KGaA、Hologic, Inc.、Agilent Technologies, Inc.、DiaSorin SpA、Illumina, Inc.、bioMérieux SA、Myriad Genetics, Inc.、Quest Diagnostics Incorporated.、Bio-Rad Laboratories, Inc.、Koninklijke Philips NV、BD、Exact Sciences Corporation、Time Medical Holding、PlexBio、Michelson Diagnostics Ltd.、MinFound Medical Systems Co., Ltd、Medonica Co. LTD、SternMed GmbH などがあります。

SKU-69603